总的来说，2025 年 ELN-DAVID 共识文件为 AML MRD 评估提供了全面的标准化框架。新共识引入了「低水平阳性（MRD-LL）」 及「最佳、警示、高风险」的定性反应分类，并细化了 MFC 和分子技术的检测阈值。此外，共识也明确了 ...

创新抗癌单抗组合获FDA突破性疗法认定益普生（Ipsen）宣布，美国FDA已授予在研单抗疗法IPN60340突破性疗法认定，与venetoclax和azacitidine（Ven-Aza）联用，用于治疗一线不适合强化治疗的急性髓系白血病（AML）。A ...

NPM1-mutated AML prognosis was refined using a new genetic model integrating co-mutations, improving risk classification and ...

急性髓系白血病（AML）的治疗在过去几十年中不断寻求突破，以超越传统的“3+7”强化诱导方案。尽管该方案在年轻、体能状态良好的患者中仍是标准治疗，但其疗效和毒性仍存在局限。BCL-2抑制剂的出现显著改变了治疗格局，尤其是在与低甲基化药物联合用于老年或不耐受患者时，已成为标准治疗。然而，关于BCL-2抑制剂维奈克拉与强化诱导化疗联合用于年轻、fit的成人AML患者的真实世界数据仍然有限，探索这一组合 ...

AVEO Oncology, an LG Chem company, (AVEO) announced today that the first patient has been successfully dosed in a Phase 1b/2 clinical trial evaluating ficlatuzumab in combination with azacitidine and ...

The "Acute Myeloid Leukemia Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's offering.The global ...

Breakthrough Therapy Designation granted for investigational therapy IPN60340 in combination with venetoclax and azacitidine in first line unfit ...

The leading Chronic Myeloid Leukemia Companies such as Kartos Therapeutics, AOP Orphan Pharmaceuticals, Biokine Therapeutics, ...

Treating acute myeloid leukemia (AML) depends on knowing what goes wrong inside cells. A new study suggests that two genetic ...

Results from the phase 3 ENDURE trial (NCT03117816), newly published in Leukemia, demonstrate that ropeginterferon alfa-2b ...